ACHN-975 TFA is a selective LpxC inhibitor with a subnanomolar inhibitory. It is against a wide range of gram-negative bacterias with low MIC values (≤1 μg mL).
ACHN-975 is a highly potent and selective LpxC inhibitor, demonstrating subnanomolar inhibitory activity. It effectively targets a broad spectrum of gram-negative bacteria, with low minimum inhibitory concentration (MIC) values (≤1 μg mL)[1].
Gramicidin A 是一种从从 B. brevis 分离出来的多肽类抗生素。Gramicidin A 是一种高度疏水的通道形成离子载体,在人工膜中形成一价阳离子可渗透的通道。Gramicidin A 诱导缺氧诱导因子 1α (HIF-1α) 的降解,并能降低人肾细胞癌小鼠异种移植模型的生长。Gramicidin A 具有抗菌、抗疟活性以及溶血活性。
IT-143B is a bacterial metabolite that has been found in S. iakyrus.1 It inhibits the proliferation of OS-RC-2 and ACHN cancer cells (IC50s = 22 and 98 μM, respectively). |1. Li, K., Liang, Z., Chen, W., et al. Iakyricidins A-D, antiproliferative piericidin analogues bearing a carbonyl group or cyclic skeleton from Streptomyces iakyrus SCSIO NS104. J. Org. Chem. 84(19), 12626-12631 (2019).
4SC-207 is a novel microtubule inhibitor , which shows strong anti-proliferative activity in a large panel of tumor cell lines with an average GI50 of 11 nM. In particular, 4SC-207 is active in multi-drug resistant cell lines, such as HCT-15 and ACHN, suggesting that it is a poor substrate for drug efflux pumps. 4SC-207 inhibits microtubule growth in vitro and in vivo and promotes, in a dose dependent manner, a mitotic delay arrest, followed by apoptosis or aberrant divisions due to chromosome alignment defects and formation of multi-polar spindles. Furthermore, preliminary data from preclinical studies suggest low propensity towards bone marrow toxicities at concentrations that inhibit tumor growth in paclitaxel-resistant xenograft models. 4SC-207 may be a potential anti-cancer agent.
Glucopiericidin A 是一种天然哌啶菌素化合物,来源于海洋衍生的链霉菌菌株。它作为葡萄糖转运蛋白 (GLUT) 的化学探针,能够抑制糖酵解。Glucopiericidin A 与 Piericidin A (PA) 联合使用时可有效抑制 ATP 依赖性丝状伪足突起,而单独使用则无效果。通过增加 PRDX1,Glucopiericidin A 降低活性氧 (ROS) 水平,诱导细胞凋亡,同时在 ACHN 小鼠异种移植物中表现出显著的抗肿瘤功效。